65
Participants
Start Date
September 25, 2024
Primary Completion Date
September 30, 2034
Study Completion Date
September 30, 2034
DiviTum® TKa assay
Will be utilized for determination of serum enzymatic activity of TK1 according to the manufacturer's instructions
CDK4/6 + Endocrine therapy
FDA-approved endocrine therapy plus CDK4/6 inhibitor. Ribociclib is the preferred CDK4/6 inhibitor. In the event this drug cannot be obtained due to insurance authorization or if there are specific side effect profile concerns from the treating physician, an alternative CDK4/6 inhibitor is allowed.
RECRUITING
Washington University School of Medicine, St Louis
Collaborators (1)
Biovica
UNKNOWN
Washington University School of Medicine
OTHER